Compare Ginkgo Bioworks Holdings Inc (DNA) vs Tenet Healthcare Corporation (THC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Tenet Healthcare Corporation — how do they compare? Ginkgo Bioworks Holdings Inc trades at $8.9 (market cap $590.53M), while Tenet Healthcare Corporation trades at $191.49 (market cap $15.82B). The key difference: Tenet Healthcare Corporation is far larger — about 26.8× Ginkgo Bioworks Holdings Inc's market cap, and Tenet Healthcare Corporation is trading nearer its 52-week high, Ginkgo Bioworks Holdings Inc nearer its low. Which is the better fit depends on your goals.
| DNA | THC | |
|---|---|---|
Market Cap | $590.53M | $15.82B |
Sector | Health | Health |
52-Week High | $16.14 | $244.80 |
52-Week Low | $5.48 | $148.38 |
Enterprise Value | $627.78M | $26.06B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DNA trades at $9.05, down 0.44% on the day, reflecting ongoing investor caution. The technical outlook is bearish, while fundamentals show significant losses with a net income margin of -201.05% and negative cash flows. Recent earnings have been mixed, missing estimates in two of the last three quarters. Analyst sentiment is divided, with a slight lean toward buy ratings amid high volatility and operational challenges.
The outlook remains challenging due to persistent losses and cash burn, though analyst coverage suggests potential long-term value. Key risks include execution missteps and intense competition in biotechnology. Investment appeal hinges on future profitability improvements and successful business model execution.
Tenet Healthcare (THC) trades at $194.81, down 4.62% today, but maintains strong fundamentals with consistent earnings beats and attractive valuation metrics. The stock shows robust profitability with 37.87% ROE and 7.79% net margin, supported by growing outpatient care operations. Technical indicators suggest near-term bearish pressure with key support at $191 and resistance at $198. Recent analyst coverage remains overwhelmingly positive with 81% buy ratings and a $235.88 consensus target.
THC presents a compelling value opportunity with below-market P/E of 9.55 and strong earnings momentum, though technical weakness and upcoming Q2 earnings on July 24 create near-term uncertainty. The expanding ambulatory care segment and defensive healthcare positioning during geopolitical tensions support long-term growth, while debt levels and hospital industry challenges remain key monitoring points.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Tenet Healthcare Corporation
Tenet Healthcare is a leading diversified healthcare services company that has strategically pivoted toward high-growth ambulatory care. Operating through United Surgical Partners International (USPI), the largest ambulatory platform in the U.S., Tenet manages an expansive network of surgical centers, acute care hospitals, and specialty facilities. The company’s focus on high-acuity services and operational efficiency, supported by its revenue cycle management subsidiary Conifer Health Solutions, positions it as a resilient leader in the evolving U.S. healthcare landscape.
Read more on THC →
